



Investment Thesis

Injective

INJ

Basic Information

Token type	Native Currency
Price	\$16.33
GCCS Classification	Smart Contract Platform, Infrastructure, Native Currency
Sector	Smart Contract Platform

Source: CoinGecko, Data as of November 4, 2024

Key Metrics

Price Range (1Y)	\$15.50- \$52.62
All-Time High	\$52.62
All-Time High Date	14 March 2024
Down From All-Time High	-69.0%
Market Capitalization	\$1.96B
Volume (24H)	\$174.46M
Circulating Supply	97.7M INJ
Max Supply	100M INJ
Total Value Locked (TVL)	\$48.6M
Annualized Staking Yield	10.72%

Source: CoinGecko, DeFiLlama, Artemis
Data as of November 4, 2024

Overview

Injective is a high-performance smart contract platform **specifically optimized for financial applications**. Injective aims to revolutionize decentralized finance (DeFi) through its unique combination of features. These include an **on-chain order book that resists Miner Extractable Value (MEV) manipulation**, providing a fair and transparent trading environment capable of handling up to **25,000 transactions per second**. The **Open Liquidity Program** is one of Injective's standout features. It allows applications to tap into a shared liquidity pool, which is highly beneficial for the entire ecosystem. By having shared liquidity, **developers building decentralized exchanges (DEXs) on Injective do not need to bootstrap their liquidity**. This significantly streamlines the development experience, enabling faster time to market and reducing the barriers to entry for new projects. The shared liquidity pool enhances the overall liquidity of the platform, making it more attractive to traders and investors.

Additionally, the **Real World Asset (RWA) module** facilitates the tokenization of assets directly on the network without relying on third-party providers. This native feature simplifies the process by **providing a more integrated and secure solution, enabling the direct tokenization of real-world assets at the network level**. This module supports both permissionless and permissioned assets, offering flexibility and control to asset issuers and holders. Therefore, the RWA module plays a crucial role in bridging the gap between traditional finance and DeFi, opening up new opportunities for asset tokenization.

Lastly, Injective is **built on the Cosmos ecosystem**, which allows it to facilitate seamless cross-chain interactions with major other Cosmos-based networks via the **Inter-Blockchain Communication (IBC) protocol**. This protocol amplifies the reach of Injective, enabling assets and data to flow freely across different blockchains. Furthermore, Injective's multi-operating system, **in EVM**, supports interoperability and developer flexibility across three smart-contract environments: Cosmos, Ethereum, and Solana.

- **November 2021:** INJ mainnet went live following incubation and token releases via Binance Labs and Launchpad.
- **Mid-2022:** Injective integrated with Ethereum and Solana, expanding its cross-chain capabilities.
- **Late 2023:** Injective launched the Open Liquidity Program to enhance shared liquidity and asset tokenization, and in **November 2023**, ONDO launched a tokenized treasury product on Injective enhancing the adoption of RWAs
- **Early 2024:** Injective introduced of the Volan mainnet upgrade, including RWA Module at the network level

Key takeaways

- **The platform features native MEV resistance** and an on-chain order book, along with a multi-OS environment. Offers an experience comparable to centralized exchanges, with features like zero-fee transactions and market manipulation protection, crucial for gaining user trust and adoption.
- The Open Liquidity Program and the Real World Asset (RWA) module **streamline liquidity sharing** and asset tokenization, simplifying the development process and providing a more integrated solution for developers.
- Injective enables **high interoperability**, making it a versatile platform for various DeFi projects.
- The INJ token can be used for governance, staking, and paying transaction fees, adding value and utility within the Injective ecosystem.

Risk factors

- **Technological Risk:** Only 60 active validators, Injective has a lower count compared to other Layer 1 blockchains
- **Competitive Risk:** Success depends on the widespread adoption of its platform by high-profile DeFi applications. Without substantial traction, Injective risks falling behind newer, more agile competitors.
- **Adoption Risk:** Ranking outside the top 50 in TVL at **\$48.6M** among all chains indicates that Injective needs to increase its user base and liquidity to compete effectively with higher-ranking protocols.

Price Performance



Source: CoinGecko. Data from November 5, 2020 - November 4, 2024

Total Value Locked



Source: Artemis. Data from November 5, 2023 - November 4, 2024

Disclaimer This document is not an offer to sell or a solicitation of an offer to buy or subscribe for securities of 21Shares AG. Neither this document nor anything contained herein shall form the basis of, or be relied upon in connection with, any offer or commitment whatsoever in any jurisdiction. This document and the information contained herein are not for distribution in or into (directly or indirectly) the United States, Canada, Australia or Japan or any other jurisdiction in which the distribution or release would be unlawful. This document does not constitute an offer of securities for sale in or into the United States, Canada, Australia or Japan. The securities of 21Shares AG to which these materials relate have not been and will not be registered under the United States Securities Act of 1933, as amended (the "Securities Act"), and may not be offered or sold in the United States absent registration or an applicable exemption from, or in a transaction not subject to, the registration requirements of the Securities Act. There will not be a public offering of securities in the United States. This document is only being distributed to and is only directed at: (i) to investment professionals falling within Article 19(5) of the Financial Services and Markets Act 2000 (Financial Promotion) Order 2005 (the "Order"); or (ii) high net worth entities, and other persons to whom it may lawfully be communicated, falling within Article 49(2)(a) to (d) of the Order (all such persons together being referred to as "relevant persons"); or (iv) persons who fall within Article 43(2) of the Order, including existing members and creditors of the Company or (v) any other persons to whom this document can be lawfully distributed in circumstances where section 21(1) of the FSMA does not apply. The securities are only available to, and any invitation, offer or agreement to subscribe, purchase or otherwise acquire such securities will be engaged in only with, relevant persons. Any person who is not a relevant person should not act or rely on this document or any of its contents. In any EEA Member State (other than the Austria, Belgium, Croatia, Denmark, Finland, France, Germany, Great Britain, Hungary, Ireland, Italy, Liechtenstein, Luxembourg, Malta, The Netherlands, Norway, Poland, Romania, Slovakia, Spain and Sweden) that has implemented the Prospectus Regulation (EU) 2017/1129, together with any applicable implementing measures in any Member State, the "Prospectus Regulation") this communication is only addressed to and is only directed at qualified investors in that Member State within the meaning of the Prospectus Regulation. Exclusively for potential investors in Austria, Belgium, Croatia, Denmark, Finland, France, Germany, Great Britain, Hungary, Ireland, Italy, Liechtenstein, Luxembourg, Malta, The Netherlands, Norway, Poland, Romania, Slovakia, Spain and Sweden the 2021 Base Prospectus (EU) is made available on the Issuer's website under www.21Shares.com. The approval of the 2021 Base Prospectus (EU) should not be understood as an endorsement by the SFSA of the securities offered or admitted to trading on a regulated market. Eligible potential investors should read the 2021 Base Prospectus (EU) and the relevant Final Terms before making an investment decision in order to understand the potential risks associated with the decision to invest in the securities. You are about to purchase a product that is not simple and may be difficult to understand. This document constitutes advertisement within the meaning of the Swiss Financial Services Act (the "FinSA") and not a prospectus. In accordance with article 109 of the Swiss Financial Services Ordinance, the Base Prospectus dated 12 November 2021, as supplemented from time to time and the final terms for any product issued have been prepared in compliance with articles 652a and 1156 of the Swiss Code of Obligations, as such articles were in effect immediately prior to the entry into effect of the FinSA, and the Listing Rules of the SIX Swiss Exchange in their version in force as of January 1, 2020. Consequently, the Prospectus has not been and will not be reviewed or approved by a Swiss review body pursuant to article 51 of the FinSA, and does not comply with the disclosure requirements applicable to a prospectus approved by such a review body under the FinSA.